<DOC>
	<DOCNO>NCT01087970</DOCNO>
	<brief_summary>The purpose study look improvement progression free survival combination pemetrexed , carboplatin ( cisplatin ) cetuximab participant recurrent metastatic squamous cell carcinoma head neck .</brief_summary>
	<brief_title>A Study Participants With Recurrent Metastatic Squamous Cell Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologic cytologic diagnosis squamous cell head neck cancer ( HNC ) Recurrent disease ( locally advance metastatic ) amenable local therapy , ( ) least 6 month since completion systemic therapy ( chemotherapy biological anticancer therapy ) , ( ii ) 1 prior multimodal therapy ( concurrent chemoradiation without sequential chemotherapy ) locally advanced HNC tumor , ( iii ) prior systemic therapy ( chemotherapy biological anticancer therapy ) metastatic disease ; OR Newly diagnose distant metastatic disease ( Stage IVc ) Prior therapy : Radiation therapy must complete least 4 week study enrollment . For palliative therapy , prior radiation therapy allow &lt; 25 % bone marrow prior radiation whole pelvis allow . Participants must recover acute toxic effect treatment prior study enrollment . Surgery ( exclude prior diagnostic biopsy ) must complete least 4 week study enrollment . Participants must fully recover acute effect surgery prior study enrollment . An estimated life expectancy least 12 week . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Biological tissue available biomarker analysis tumor tissue . Disease status must measurable defined Response Evaluation Criteria Solid Tumors ( RECIST ) . The index lesion must prior irradiated area . Positron emission tomography ( PET ) scan ultrasounds may use lesion measurement . Participant compliance geographic proximity allow adequate followup . Adequate organ function define follow : Bone marrow reserve : absolute neutrophil ( segmented band ) count ( ANC ) great equal 1.5 × 10⁹/liter ( L ) , platelet great equal 100 × 10⁹/L , hemoglobin great equal 9 grams/deciliter ( g/dL ) . Hepatic : bilirubin le equal 1.5 × upper limit normal ( ULN ) ; alkaline phosphatase ( ALP ) , aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) less equal 3.0 × ULN ( ALP , AST , ALT le equal 5.0 × ULN acceptable liver tumor involvement ) . Renal : calculated creatinine clearance ( CrCl ) great equal 45 milliliters/minute ( mL/min ) . For woman : Must surgically sterile , postmenopausal , compliant medically approve contraceptive regimen 6 month treatment period ; must negative serum urine pregnancy test within 7 day study enrollment , must breastfeed . For men : Must surgically sterile compliant contraceptive regimen 6 month treatment period . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry . Are receive concurrent chronic systemic immune therapy , chemotherapy disease cancer . Concurrent administration antitumor therapy . Known prior allergic/hypersensitivity reaction component study treatment . Serious concomitant systemic disorder ( example , active infection ) psychiatric disorder , opinion investigator , would compromise participant 's ability complete study . Have serious cardiac disease , symptomatic angina , unstable angina , history myocardial infarction previous 12 month . Second primary malignancy clinically detectable time consideration study enrollment . Have another primary malignancy HNC , unless prior malignancy treat least 2 year previously evidence recurrence . Exception : Participants history situ carcinoma cervix , nonmelanoma skin cancer , lowgrade ( Gleason score less equal 6 ) localize prostate cancer eligible even diagnose treat less 2 year previously . Nasopharyngeal , paranasal sinus , lip , salivary gland cancer . Presence clinically significant ( physical exam ) thirdspace fluid collection ; example , ascites pleural effusion control drainage procedure prior study entry . Have peripheral neuropathy Common Terminology Criteria Adverse Events ( CTCAE ) Grade 1 high . Have central nervous system ( CNS ) metastases ( unless participant complete successful local therapy CNS metastases corticosteroid least 4 week start study therapy ) . Brain imaging require symptomatic participant rule brain metastasis , require asymptomatic participant . Inability interrupt aspirin nonsteroidal antiinflammatory agent , aspirin dose less equal 1.3 gram per day , 5day period ( 8day period longacting agent , piroxicam ) . Unable unwilling take folic acid , vitamin B12 , prophylactic corticosteroid . Recent ( within 30 day enrollment ) concurrent yellow fever vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Pharynx</keyword>
	<keyword>Larynx</keyword>
	<keyword>Nose</keyword>
	<keyword>Parathyroid</keyword>
</DOC>